PMBS - der Ausbruch kommt !
Seite 1 von 11 Neuester Beitrag: 25.04.21 01:01 | ||||
| Eröffnet am: | 19.01.14 14:24 | von: Tuedi2005 | Anzahl Beiträge: | 266 |
| Neuester Beitrag: | 25.04.21 01:01 | von: Mariaxppea | Leser gesamt: | 31.105 |
| Forum: | Hot-Stocks | Leser heute: | 5 | |
| Bewertet mit: |  | |||
| Seite: < | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 11 > | ||||
PuraMed engages in the research, development and marketing of non-prescription medicinal and healthcare products. The company emphasizes science as a key component for its success. By partnering with world-class researchers and physicians to conduct and publish world-class research on its products, PuraMed believes it will gain acceptance and credibility from consumers and medical professionals at a much faster and greater rate.
For its initial product line, the company uses a unique sublingual (under the tongue) delivery system, taking advantage of the capillary structure under the tongue which is very close to the surface. Sublingual delivery enables fast absorption and action. It also bypasses the liver and digestive system, avoiding the destruction of the active ingredients by these organs. This allows for lower dosage requirements and increased safety.
PuraMed is currently launching its first product, LipiGesic® M for the treatment of migraine headaches, into the U.S. national retail market. This is a very large market, with approximately 50 million sufferers in the U.S. alone. Migraine headaches are considered to be the most expensive brain disorder in the U.S., costing the economy more than $31 billion in 2010.
A multi-site, double-blind placebo-controlled study, conducted by three nationally recognized headache specialists, was published in a top-tier medical journal in July 2011. This study concluded that LipiGesic M is a highly effective and safe first-line abortive treatment for migraine sufferers. When compared to a meta-analysis of the number one selling prescription treatment, the results of the LipiGesic® M study show it offers a number of advantages. In addition to superior pain relief, LipiGesic® M provides relief from the associated symptoms. It also offers a vastly improved safety profile, no known drug interactions, does not require a physician visit or prescription, and it cuts the treatment cost by at least 75%. These are very powerful advantages, especially for a non-prescription treatment.
In addition to LipiGesic® M, the company also intends to launch two other sublingual gel products in its LipiGesic product line. LipiGesic® H is designed to provide rapid relief from tension-type headaches. More than 100 million people suffer from chronic and episodic tension-type headaches in the U.S. LipiGesic PM is designed to provide relief from insomnia and other sleep disorders. There are more 70 million people who suffer from sleep disorders in the U.S. alone.
The LipiGesic product line effectively addresses three large underserved markets. In addition, the company has approximately 20 other unique products in its pipeline, addressing a broad spectrum of self-limiting disease states including acne, rosacea, age spots and canker sores.
The company believes that by improving the efficiency of delivery, it can provide products that offer superior relief versus current treatment while also dramatically increasing safety and cutting treatment costs significantly.
Market Drivers
50 million migraine sufferers
70 million insomnia sufferers
Total economic cost of migraine headaches exceeded $31 Billion in the United States in 2010. Migraine headaches represent the most costly brain disorder in the United States.
By using sublingual (under the tongue) delivery, the medication is able to work much faster than taking pills.
Sublingual delivery also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This enables the Company to achieve broad distribution quickly and at low cost.
There are NO serious adverse events associated with LipiGesic® products for migraine, insomnia or tension headaches.
Unique PuraMed Delivery System
Sublingual delivery (meaning under the tongue) is a superior delivery system to pills because the sublingual delivery works much faster and lower dosage is required. The capillaries under the tongue are extremely close to the surface creating very fast absorption and action. Sublingual delivery not only works faster than most other delivery systems but it also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Distribution
Non-prescription products reach U.S. consumers through approximately 80,000 chain and independent drug, food and mass merchandise retailers (including club stores), 116,000 convenience stores, 4,500 specialty nutrition and health stores, as well as via direct marketing through television, radio, catalogues and the Internet. PuraMed plans to market and distribute its products through mainstream chain drug, independent drug, mass merchandiser, food and warehouse stores. Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This background will enable the Company to achieve broad distribution quickly and at better rates.
RECENT HIGHLIGHTS
Distributing product in Walgreens stores across the nation, with additional key retail chains to follow.
News and Developments
PuraMed BioScience announced today that the independent clinical study of their LipiGesic® M migraine product has been accepted for publication by a top ranked medical journal. The clinical study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic® M for the treatment of acute migraines.
PuraMed BioScience announced today that it has entered into an agreement with Double Pump, Inc. designed to enhance marketing efforts and product awareness surrounding the national retail launch of the Company"s products.
Market Opportunity
LipiGesic® M – Migraine
Over 50 million suffer
1 billion + occurrences/yr.
Majority rely on non prescription medications
Current migraine relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® H – Tension
Over 102 million suffer from chronic and episodic tension-type headache
1 billion occurrences/year
Current tension relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® PM -Insomnia
70 million suffer
5 billion occurrences/yr.
Current insomnia products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
Da bin ich mal sehr auf die ersten Verkaufszahlen gespannt.
Das Migränemittel hat wohl nicht die üblichen Nebenwirkungen wie etwa Ibuprofen und könnte der ganz große Renner in den USA werden !
KEIN TAGESZOCK, sondern ein massiver Anstieg aufgrund der realen Daten, die kommen werden.
Und DASS es die Produkte gibt und DASS sie verkauft werden, ist von Usern im ihub in den vergangenen Tagen mit Fotos und Videos eindrucksvoll dokumentiert worden
(es gab einige Zeit massive Versuche, genau das infrage zu stellen !)
Deswegen: erst mal schaun, wie der Handel startet und dann einsteigen - aber 2014 könnte definitiv ein GROßES Jahr für PMBS werden imo.
Wenn nur 10 Prozent der Amerikaner Migräneprobleme haben und von denen auf Sicht nur 10 Prozent LipiGesic M kaufen, reden wir hier nur für dieses eine Mittel über Millionen Dollar an Gewinn.
LG, biotech
Optionen
| Boardmail an "biotech1x1" |
Wertpapier: Puramed Bioscience |
Klar, daß die Aktie bei 0,002 USD steht.
Außerdem haben die dieses Unternehmen als Hersteller für ihr Migräne-Mittel:
http://hillestadlabs.com/
Zitat aus 10-Q:
"Hillestad Pharmaceuticals is an FDA licensed prescription drug manufacturer. "
Danach sieht mir die Seite aber nicht wirklich aus bzw. die Aussage macht erstmal "größere" Hoffnungen, beim Anklicken der Seite erfährt man dann eine relative Enttäuschung (oder gehts nur mir so?).
LG, biotech
Optionen
| Boardmail an "biotech1x1" |
Wertpapier: Puramed Bioscience |
Natürlich ist die die OTC immer hoch spekulativ, aber ich sehe hier die Chancen und bin bereit, dafür ein hohes Risiko zu gehen.
Die werden wohlin der Lage sein, Medikamente zu produzieren...die kann man jetzt ja auch ganz real erwerben.
ABER: Wenn PMBS das Migränemittel landesweit gut verkaufen kann, sollten Subpenny-Preise bald der Vergangenheit angehören mMn.
Aber grundsätzlich mag ich die Begeisterungsfähigkeit der Amerikaner, die sich erstmal grundpositiv über die aktuelle Entwicklung von PMBS auslassen und den riesigen Markt für ein neuartiges Migrgänemittelsehen anstatt sofort immer auf die Risiken zu schauen.
Wenn die Verkaufszahlen hier gut einschlagen sind alle historischen Kurse und Marketingmeldungen von 2012 eh vollkommen uninteressant und Schnell von vorvorgestern.
Wie auch immer: mit einer kleinen Posi hier einsteigen und auf einen heftigen Ausbruch der Aktie zu spekulieren ist mir das Risiko wert. Sollte aber wirklich jede für sich in Ruhe prüfen...ist ja heute zum Glück Feiertag in den USA !
Optionen
| Boardmail an "extrachili" |
Wertpapier: Puramed Bioscience |
Ich persönlich hätte auch gerne heute schon gesehen, wie es in den Staaten weitergeht !
http://www.puramedbioscience.com/2013/05/13/...igraine-pain-reliever/
PuraMed BioScience® Inc., Announces Manufacturing and Packaging Vendors for LipiGesic® M, its Highly Effective, Non-Prescription Migraine Pain Reliever
by admin on May 13, 2013 in Press Releases
SCHOFIELD, Wis., April 18, 2013 /PRNewswire/ – PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces its production vendors for the mass manufacturing and packaging of LipiGesic® M (www.lipigesic.com/about) its clinically tested, non-drowsy, migraine relief product.
“Through our current relationships with our third-party vendors, PuraMed has the established and proven infrastructure necessary to execute manufacturing, packaging, and distribution of LipiGesic M to an expanded number of retail outlets as orders are submitted,” said Russell Mitchell , CEO of PuraMed BioScience.
Product Manufacturing
PuraMed has contracted bulk manufacturing of LipiGesic products to Hillestad Pharmaceuticals, a Woodruff, Wisconsin-based, fully licensed prescription and OTC drug manufacturer. Hillestad also provides quality assurance testing. Hillestad Pharmaceuticals is fully compliant with all Good Manufacturing Practices (GMP) and other regulations set forth by the US Food and Drug Administration (FDA). www.hillestadlabs.com
Product Packaging
The bulk material is then packaged into individual, pre-measured unit dose sachets by the Unette Corporation in Randolph, New Jersey. Unette is fully licensed and compliant with all FDA regulations for the packaging of OTC products.
The external packaging including the box, box inserts, and 6-pack retail display trays has been awarded to Proteus Packaging located in Franklin, Wisconsin. Proteus has obtained the necessary certifications to ensure and maintain quality of the LipiGesic M product.
Online Distribution
PuraMed BioScience will utilize Great Lakes Fulfillment, of Lewiston, Maine for all of its e-commerce and retail distribution.
Expansion to Additional Retail Drug Chains
Currently, LipiGesic M is distributed in approximately 15,000 Walgreen’s and CVS/pharmacy stores across the United States. PuraMed plans to expand the retail placement of LipiGesic M, its clinically tested, natural migraine relief product into an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains.
“With our manufacturing, packaging and fulfillment structure in place, PuraMed plans to ready its marketing and sales staff to begin the next phase of our product marketing campaign as we continue with our retail expansion plans,” said Mr. Mitchell.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com
Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Contact:
Melissa Diaz ,
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com
hat es mMn in sich:
Expansion to Additional Retail Drug Chains
Currently, LipiGesic M is distributed in approximately 15,000 Walgreen’s and CVS/pharmacy stores across the United States. PuraMed plans to expand the retail placement of LipiGesic M, its clinically tested, natural migraine relief product into an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains.
Mit dem Verkauf bei Walgreen und CVS haben sie jetzt ja gerade erst begonnen - und da kommen mit den großen Ketten dann noch sehr viel mehr Verkaufsstellen dazu.
Da kann man schon mal ein bißchen Fantasie über die Verkaufszahlen und Erlöse entwickeln, finde ich.
Guter Wochenstart soweit...wenn jetzt noch News kämen, wäre das natürlich sehr geil.